ES2134346T3 - Virus citopatico para el tratamiento y la profilaxis de la neoplasia. - Google Patents

Virus citopatico para el tratamiento y la profilaxis de la neoplasia.

Info

Publication number
ES2134346T3
ES2134346T3 ES94910177T ES94910177T ES2134346T3 ES 2134346 T3 ES2134346 T3 ES 2134346T3 ES 94910177 T ES94910177 T ES 94910177T ES 94910177 T ES94910177 T ES 94910177T ES 2134346 T3 ES2134346 T3 ES 2134346T3
Authority
ES
Spain
Prior art keywords
replication phenotype
cells
neoplastic cells
viral
neoplastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94910177T
Other languages
English (en)
Inventor
Francis Mccormick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onyx Pharmaceuticals Inc
Original Assignee
Onyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Pharmaceuticals Inc filed Critical Onyx Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2134346T3 publication Critical patent/ES2134346T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

SE PRESENTAN METODOS Y COMPOSICIONES PARA TRATAR CONDICIONES NEOPLASTICAS MEDIANTE TERAPIA BASADA EN VIRUS. SE ADMINISTRAN DE VIRUS MUTANTES QUE CARECEN DE PROTEINAS VIRALES QUE SE UNEN Y/O INACTIVAN P 53 O RB A UN PACIENTE QUE TENGA UN NEOPLASMA QUE COMPRENDA CELULAS QUE CAREZCAN DE FUNCION P 53 Y/O RB. LOS VIRUS MUTANTES SON CAPACES DE PRODUCIR SUBSTANCIALMENTE UN FENOTIPO DE REPLICACION EN LAS CELULAS NEOPLASTICAS PERO SON SUBSTANCIALMENTE INCAPACES DE PRODUCIR UN FENOTIPO DE REPLICACION EN CELULAS NO REPLICANTES, NO NEOPLASTICAS QUE TENGAN UNA FUNCION P 53 Y/O RB ESENCIALMENTE NORMAL. LA GENERACION PREFERENCIAL DEL FENOTIPO DE REPLICACION EN LAS CELULAS NEOPLASTICAS DA COMO RESULTADO UNA MUERTE PREFERENCIAL DE LAS CELULAS NEOPLASTICAS, TANTO DIRECTAMENTE O MEDIANTE LA EXPRESION DE UN GEN CITOTOXICO EN LAS CELULAS QUE EXPRESAN UN FENOTIPO DE REPLICACION VIRAL.
ES94910177T 1993-02-16 1994-02-16 Virus citopatico para el tratamiento y la profilaxis de la neoplasia. Expired - Lifetime ES2134346T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1752593A 1993-02-16 1993-02-16

Publications (1)

Publication Number Publication Date
ES2134346T3 true ES2134346T3 (es) 1999-10-01

Family

ID=21783090

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94910177T Expired - Lifetime ES2134346T3 (es) 1993-02-16 1994-02-16 Virus citopatico para el tratamiento y la profilaxis de la neoplasia.
ES98121753T Expired - Lifetime ES2157109T3 (es) 1993-02-16 1994-02-16 Virus citopaticos para el tratamiento y la profilasis de la neoplasia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES98121753T Expired - Lifetime ES2157109T3 (es) 1993-02-16 1994-02-16 Virus citopaticos para el tratamiento y la profilasis de la neoplasia.

Country Status (11)

Country Link
EP (2) EP0689447B1 (es)
JP (2) JP3556666B2 (es)
AT (2) ATE199568T1 (es)
AU (1) AU682854B2 (es)
CA (1) CA2152941C (es)
DE (2) DE69426841T2 (es)
DK (2) DK0931830T3 (es)
ES (2) ES2134346T3 (es)
GR (2) GR3030385T3 (es)
PT (1) PT931830E (es)
WO (1) WO1994018992A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
EP0575518A1 (en) 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5516631A (en) * 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
EP1314431B1 (en) 1993-04-30 2008-07-16 Wellstat Biologics Corporation Purified compositions of Newcastle disease virus
US5776743A (en) * 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
AU716045B2 (en) * 1994-11-28 2000-02-17 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US20030026789A1 (en) * 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
WO1997007828A1 (en) * 1995-08-30 1997-03-06 The Regents Of The University Of California Therapy for cellular accumulation in chronic inflammatory diseases
US6133243A (en) * 1996-02-22 2000-10-17 Onyx Pharmaceuticals, Inc. Liposomal-viral DNA complexes for treating disease
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
AU4592697A (en) * 1996-09-24 1998-04-17 Dana-Farber Cancer Institute Method of targeting malignant cells using an e2f responsive promoter
JP2001505766A (ja) * 1996-11-18 2001-05-08 マクギル ユニバーシティー アポトーシスと生長を調節するアデノウイルスベクターを有する、有糸分裂後のニューロン
US6080578A (en) * 1996-12-31 2000-06-27 Onyx Pharmaceuticals, Inc. Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
HU226602B1 (en) * 1998-10-15 2009-04-28 Canji Selectively replicating viral vectors, pharmaceutical preparations containing them and process for producing them
JP2002527455A (ja) * 1998-10-15 2002-08-27 カンジ，インコーポレイテッド 組換え欠失アデノウイルスベクター
US20020037274A1 (en) * 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
AU2145300A (en) * 1998-11-18 2000-06-05 Canji, Inc. Adenoviral vectors
GB9906815D0 (en) 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
IL145899A0 (en) 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
DE19929569A1 (de) * 1999-06-21 2000-12-28 Holm Per Sonne Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
ATE364091T1 (de) * 1999-11-15 2007-06-15 Onyx Pharma Inc Ein oncolytisches adenovirus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
JP2004536572A (ja) 2001-02-23 2004-12-09 セル・ジェネシス・インコーポレイテッド 新規ベクター構築物
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
EP1944035A1 (en) 2002-05-09 2008-07-16 Oncolytics Biotech Inc. Method for reducing pain using oncolytic viruses
AU2011221393A1 (en) * 2002-05-27 2011-09-29 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
CA2487811A1 (en) * 2002-05-27 2003-12-04 Per Sonne Holm Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors
RU2393221C2 (ru) * 2002-10-15 2010-06-27 Пер Сонне ХОЛЬМ Аденовирус с обращенной генной экспрессией и его применение
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
EP1897938B9 (en) 2003-07-21 2011-08-31 Transgene SA Polypeptide having an improved cytosine deaminase activity
US20070110719A1 (en) * 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
KR100756055B1 (ko) * 2006-01-27 2007-09-07 연세대학교 산학협력단 신생혈관 생성을 조절하는 재조합 아데노바이러스
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
US20110287089A1 (en) 2009-01-13 2011-11-24 Karola Rittner Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2012022496A2 (en) 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
CA3060573A1 (en) 2017-04-21 2018-10-25 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells

Also Published As

Publication number Publication date
DE69417734D1 (de) 1999-05-12
EP0689447A4 (en) 1997-06-04
GR3030385T3 (en) 1999-09-30
DK0931830T3 (da) 2001-06-11
DE69417734T2 (de) 1999-10-07
ATE178490T1 (de) 1999-04-15
DE69426841T2 (de) 2001-09-06
DK0689447T3 (da) 1999-10-18
CA2152941A1 (en) 1994-09-01
EP0931830A3 (en) 2000-07-12
ES2157109T3 (es) 2001-08-01
CA2152941C (en) 2003-04-22
JP3556666B2 (ja) 2004-08-18
ATE199568T1 (de) 2001-03-15
EP0931830A2 (en) 1999-07-28
JPH08507076A (ja) 1996-07-30
JP2004115543A (ja) 2004-04-15
EP0689447A1 (en) 1996-01-03
AU682854B2 (en) 1997-10-23
DE69426841D1 (de) 2001-04-12
PT931830E (pt) 2001-08-30
EP0689447B1 (en) 1999-04-07
GR3035914T3 (en) 2001-08-31
AU6272294A (en) 1994-09-14
WO1994018992A1 (en) 1994-09-01
EP0931830B1 (en) 2001-03-07

Similar Documents

Publication Publication Date Title
ES2134346T3 (es) Virus citopatico para el tratamiento y la profilaxis de la neoplasia.
WO1998029555A3 (en) Cytopathic viruses for therapy and prophylaxis of neoplasia
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
LU93101I2 (fr) Imlygic-talimogene laherparepvec
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
WO1995032298A3 (en) Safe vectors for gene therapy
ES554967A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
AU3698697A (en) Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament
WO1995026411A3 (en) Composition and methods for creating syngeneic recombinant virus-producing cells
AU1062092A (en) Sulfonic stilbene derivatives in the treatment of viral diseases
ES2113910T3 (es) Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
NO940810L (no) Behandling av virusinfeksjoner
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
DE69422980T2 (de) Extrakte von Piliostigma thonningii, deren Verwendung und diese enthaltende Zubereitungen
DE69006187D1 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.
AU630099B2 (en) Non-reverting rna viruses
TW251235B (en) Treatment of viral infections

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 689447

Country of ref document: ES